Introduction:
GLIMIDAC is a comprehensive range of oral antidiabetic medications designed for effective glycemic control in patients with type 2 diabetes mellitus. It includes Glimepiride monotherapy and fixed-dose combinations with Metformin (SR) to cater to varying degrees of insulin resistance and beta-cell function impairment.
Formulated to ensure reliable glucose-lowering efficacy and patient compliance, the GLIMIDAC range is available in Blister and ALU-ALU packaging (10 x 10 or 10 x 15 tablets) for enhanced stability and extended shelf life.
Product Range & Benefits:
1. GLIMIDAC-1 / 2 / 3 / 4
-
Composition: Glimepiride 1 mg / 2 mg / 3 mg / 4 mg
-
Packaging: BILSTER (1 mg, 2 mg), ALU-ALU (3 mg, 4 mg) | 10 x 10 Tablets
-
Use: Monotherapy in newly diagnosed or mild type 2 diabetes cases
Key Benefits:
-
Stimulates insulin release from pancreatic β-cells
-
Suitable for stepwise diabetes management
-
Cost-effective and well-tolerated
2. GLIMIDAC M1 / M2
-
Composition: Glimepiride 1 mg / 2 mg + Metformin 500 mg (SR)
-
Packaging: BILSTER | 10 x 10 Tablets
-
Use: For dual therapy in moderate insulin resistance and impaired fasting glucose
Key Benefits:
-
Complementary mechanism of action
-
Enhances glycemic control with minimal hypoglycemia
-
Once-daily convenience
3. GLIMIDAC M1 FORTE / M2 FORTE / M3 FORTE / M4 FORTE
-
Composition:
-
M1 FORTE: Glimepiride 1 mg + Metformin 1000 mg (SR)
-
M2 FORTE: Glimepiride 2 mg + Metformin 1000 mg (SR)
-
M3 FORTE: Glimepiride 3 mg + Metformin 1000 mg (SR)
-
M4 FORTE: Glimepiride 4 mg + Metformin 1000 mg (SR)
-
-
Packaging: BILSTER | 10 x 10 or 10 x 15 Tablets
-
Use: For advanced or uncontrolled diabetes requiring intensive dual therapy
Key Benefits:
-
Optimal for overweight patients with insulin resistance
-
Improves HbA1c and postprandial glucose
-
Helps reduce long-term microvascular complications
Indications:
-
Type 2 Diabetes Mellitus (T2DM)
-
Inadequate glycemic control on monotherapy
-
Patients with insulin resistance or high HbA1c levels
-
Step-up therapy for uncontrolled diabetes
Dosage and Administration:
-
Monotherapy (GLIMIDAC-1/2/3/4): Once daily with breakfast or first main meal
-
Combination Therapy (M1/M2 & FORTE variants): Once daily with meals to reduce gastrointestinal side effects
-
Dose adjustment as per physician’s recommendation based on blood glucose monitoring
Precautions & Warnings:
-
Risk of hypoglycemia, especially in elderly or renal-impaired patients
-
Monitor renal function periodically (especially with Metformin)
-
Avoid alcohol consumption while on therapy
-
Not advised in Type 1 Diabetes or diabetic ketoacidosis
-
Use cautiously during pregnancy and lactation
Possible Side Effects:
-
Mild hypoglycemia, dizziness, or hunger
-
Gastrointestinal discomfort (nausea, bloating) with Metformin
-
Rare allergic skin reactions
-
Vitamin B12 deficiency with long-term Metformin use
Conclusion:
GLIMIDAC offers a versatile, clinically proven solution for effective diabetes management—ranging from mild to severe insulin resistance. With both Glimepiride monotherapy and Glimepiride + Metformin SR fixed-dose combinations, GLIMIDAC supports physicians in customizing treatment strategies for better long-term glycemic control and improved patient adherence.
Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.
For more such product information and similar product category Diabetic
You can also contact us https://diabetes-cardiac.com/contact-us/
